ly3437943 retatrutide 30 mg — ≥99% HPLC, COA Included Retatrutide (LY3437943) | GIP/GLP-1/GCGR agonist
Description
In Phase 2 that meant nausea, vomiting, diarrhea, and constipation, with 6 to 16 percent of people stopping depending on dose
This transition requires more than just the medication itself
District Judge Karen S
GLP-1 receptor agonist 7 generates cAMP under the mediation of GLP-1R with an EC 50 of 0.2 nM
Sources: Kleinert M, et al
However, serious complications, such as gallstones and intestinal obstruction, have been reported in a small proportion of GLP-1 users
